Robert I Tepper
CIK 1192595 · President, R&D · last filed 2023-02-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BPMC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BOSTON, MA 02215
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VYGR | 10%+ Owner | 4,813,933 | $1.90 | $9.15M | -$16.15M | 2 | 2023-02-01 |
| RVMD | 10%+ Owner | 129,258 | $177.96 | $23.00M | -$34.01M | 2 | 2022-06-10 |
| Jounce Therapeutics, Inc. (JNCE) Delisted | Director | 3,102,372 | $1.88 | $5.83M | -$630.5K | 6 | 2020-11-23 |
| Neon Therapeutics, Inc. (NTGN) Delisted | Director | 0 | — | — | $0 | 3 | 2020-05-06 |
| FULC | 10%+ Owner | 5,962,202 | $3.65 | $21.76M | $6.50M | 1 | 2019-07-22 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | Director | 3,034,083 | $33.99 | $103.13M | $4.00M | 3 | 2019-06-10 |
| Allena Pharmaceuticals, Inc. (ALNA) Delisted | Director | 2,790,964 | $0.07 | $209.3K | $3.01M | 3 | 2019-06-07 |
| MyoKardia, Inc. (MYOK) Delisted | 10%+ Owner | 146,075 | — | — | -$129.30M | 4 | 2018-02-13 |
| CTMX | 10%+ Owner | 4,349,864 | $2.28 | $9.92M | -$1.20M | 3 | 2017-10-04 |
| KALA | Director | 649 | $0.19 | $123 | $0 | 2 | 2017-07-26 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | 10%+ Owner | 4,704,964 | $68.49 | $322.24M | -$1.04M | 2 | 2017-04-10 |
| Blueprint Medicines Corp (BPMC) Delisted | 10%+ Owner | 3,453,753 | $129.46 | $447.12M | -$211.65M | 2 | 2017-02-28 |
| Sage Therapeutics, Inc. (SAGE) Delisted | 10%+ Owner | 138,917 | $8.68 | $1.21M | -$132.81M | 3 | 2016-08-19 |
| EDIT | 10%+ Owner | 3,906,176 | $2.35 | $9.18M | $0 | 2 | 2016-08-16 |
| bluebird bio, Inc. (BLUE) Delisted | Director | 4,451 | $4.97 | $22.1K | -$24.88M | 7 | 2015-02-04 |
| MILLENNIUM PHARMACEUTICALS INC (MLNM) Delisted | President, R&D | 111,587 | — | — | -$255.6K | 1 | 2007-02-13 |
Recent Filings · Page 5 of 5
46 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-01-23 | bluebird bio, Inc. (BLUE) Delisted | Sell (S) | −250,000 | -$5.98M | EDGAR |
| 2014-01-17 | bluebird bio, Inc. (BLUE) Delisted | Sell (S) | −307,000 | -$6.88M | EDGAR |
| 2014-01-14 | bluebird bio, Inc. (BLUE) Delisted | Sell (S) | −340,000 | -$7.45M | EDGAR |
| 2013-12-18 | bluebird bio, Inc. (BLUE) Delisted | Other (J) | −1,405,185 | $0 | EDGAR |
| 2013-06-26 | bluebird bio, Inc. (BLUE) Delisted | Conv (C) | +4,734,248 | $0 | EDGAR |
| 2007-02-13 | MILLENNIUM PHARMACEUTICALS INC (MLNM) Delisted | Sell (S) | −22,500 | -$255.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.